Skip to main content

Advertisement

SpringerLink
Log in

Response to “Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?”

  • Rebuttal Letter
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 16 January 2017

The Original Article was published on 16 January 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA (2016) Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. doi:10.1007/s10549-016-4080-9

    Google Scholar 

  2. Dawood S, Broglio K et al (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21:2169–2174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Marshall EM, Bertaut A, Desmoulins I et al (2016) Prognostic factors of survival among women with metastatic breast cancer and impact of primary or secondary nature of disease on survival: a French population-based study. Breast J. doi:10.1111/tbj.12717

    PubMed  Google Scholar 

  4. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC (2015) Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer 112(9):1445–1451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, Canturk Z, Utkan Z, Ozaslan C, Evrensel T, Uras C, Aksaz E, Soyder A, Ugurlu UM, Col C, Cabioglu N, Bozkurt B, Sezgin E, Johnson R, Lembersky BC (2016) A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). 2016 ASCO Annual Meeting. Abstract 1005

  6. Badwe R, Parmar V, Hawaldar R et al (2013) Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial. SABCS 2013. Abstract S2-02

  7. King TA, Lyman J, Gonen M et al (2016) A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). 2016 ASCO Annual Meeting. Abstract 1006

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada

    Wendie D. den Brok, Caroline H. Speers, Lovedeep Gondara, Emily Baxter & Caroline A. Lohrisch

  2. Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada

    Scott K. Tyldesley

Authors
  1. Wendie D. den Brok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline H. Speers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lovedeep Gondara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emily Baxter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Scott K. Tyldesley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Caroline A. Lohrisch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendie D. den Brok.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

den Brok, W.D., Speers, C.H., Gondara, L. et al. Response to “Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?”. Breast Cancer Res Treat 162, 397–398 (2017). https://doi.org/10.1007/s10549-017-4114-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4114-y

Keywords

Search

Navigation